Risk of subsequent myeloid neoplasms after radiotherapy treatment for a solid cancer among adults in the United States, 2000–2014

Keyphrases

• Solid Cancer 100%
• United States 100%
• Standardized Incidence Ratio 100%
• Radiotherapy Treatment 100%
• Myeloid Neoplasms 100%
• Acute Myeloid Leukemia 50%
• Radiotherapy 33%
• Prostate 16%
• Cancer Survivors 16%
• BCR-ABL1 16%
• Chronic Myeloid Leukemia 16%
• Cytogenetic Abnormalities 16%
• Uterine Cancer 16%
• Chemotherapy 8%
• Survivors 8%
• Cancer Treatment 8%
• Leukemia Subtype 8%
• Excess Absolute Risk 8%
• Radioiodine 8%
• Population-based Cancer Registry 8%
• Acute Promyelocytic Leukemia 8%
• US Population 8%
• Cancer Stage 8%
• Risk-benefit 8%
• First Primary Cancer 8%
• Thyroid Cancer Survivors 8%
• Cancer Registry Data 8%
• Prostate Cancer Survivors 8%
• Diagnostic Precision 8%
• III-N 8%
• Acute Myeloid Leukemia with Myelodysplasia-related Changes 8%

Medicine and Dentistry

• Malignant Neoplasm 100%
• Neoplasm 100%
• Radiation Therapy 100%
• Standardized Incidence Ratio 100%
• Acute Myeloid Leukemia 58%
• Chronic Myelogenous Leukemia 16%
• Uterine Cancer 16%
• Primary Tumor 8%
• Diagnosis 8%
• Thyroid Gland 8%
• Cancer Therapy 8%
• Prostate Cancer 8%
• Cancer Registry 8%
• Myelodysplastic Syndrome 8%
• Radioactive Iodine 8%
• Thyroid Cancer 8%
• Acute Promyelocytic Leukemia 8%
• Stage 3 Cancer 8%
• Chemotherapy 8%